A CMS advisory panel is opposing a policy that would cut payments by 22.5 percent for drugs providers purchasing under the 340B drug discount program, according to Health Leaders Media. As it ...
CMS will hold off on updating the controversial hospital star ratings pending a review from an expert panel, an agency spokesperson confirmed to Healthcare Dive on Friday. CMS is convening a technical ...
The upshot is that the CMS committee backed Provenge for on-label use, but not for use in patients whose cancer hasn't progressed. Next, the agency will have to consider the panel's advice--and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback